A question-and-answer session will follow Dova’s remarks.
DURHAM, N.C., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals (NASDAQ:DOVA), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for rare diseases where there is a high unmet need, will host a conference call on Thursday, November 9, 2017 at 4:30 p.m. EST to discuss third quarter 2017 financial results and recent operational highlights. A question-and-answer session will follow Dova’s remarks.
To participate on the live call, please dial 866-550-8145 (domestic) or +1-430-775-1344 (international) and provide the conference ID 9965479 five to 10 minutes before the start of the call.
A live audio webcast of the call will also be available via the “Investor Relations” page of the Dova website, www.dova.com. Please log on through Dova’s website approximately 10 minutes before the scheduled start time. A replay of the webcast will be archived on Dova’s website for 90 days following the call.
About Dova Pharmaceuticals, Inc.
Dova is a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is a high unmet need, with an initial focus on addressing thrombocytopenia. Dova’s lead drug candidate, avatrombopag, has successfully completed two pivotal Phase 3 clinical trials for the treatment of thrombocytopenia in patients with CLD scheduled to undergo a procedure and an NDA has now been submitted to FDA for this initial indication.
Contacts
Doug Blankenship
(919) 748-5975
dblankenship@dova.com
Westwicke Partners
John Woolford
(443) 213-0506
john.woolford@westwicke.com
